Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Journey Medical CorporationNASDAQ: DERM
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $4.76M, compared with -$7.99M a year earlier. Trailing-twelve-month accounts receivables was -$6.59M. Over 3 fiscal years it compounded at +53.2% a year.
Context
- Accounts receivables amounted to 31.3% of revenue in FY2025, up 23.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $4.76M or moves back toward the trailing-twelve-month quarterly average of -$1.65M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (19.34M) USD
- Year-over-year change
- -532.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.34M) | -532.2% |
| FY2024 | 2024-12-31 | 4.48M | -64.3% |
| FY2023 | 2023-12-31 | 12.55M | +333.3% |
| FY2022 | 2022-12-31 | (5.38M) | -800.5% |
| FY2021 | 2021-12-31 | 768K | — |
Accounts Receivables vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.2% is the 4th highest of 10, against a peer median of -70.9%.
- Accounts receivables amounts to 10.2% of revenue for DERM, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$15.58M CAD | +1667.9% | — | 5.7% | |
| LTM Mar 2026 | $6.59M USD | -26.2% | +53.2% | 10.2% | |
| LTM Mar 2026 | €5.03M EUR | -442.9% | — | 30.8% | |
| LTM Mar 2026 | $3.64M USD | +1144.1% | — | 25.1% | |
| LTM Mar 2026 | $3.09M USD | -125.5% | — | 2.7% | |
| LTM Mar 2026 | $2.71M USD | -76.9% | +101.6% | 5.3% | |
| LTM Mar 2026 | $1.5M USD | -42.4% | — | 84.7% | |
| FY2025 | €816.45K EUR | -70.9% | -40.3% | 18.2% | |
| LTM Mar 2026 | $133K USD | -337.5% | — | 1.4% | |
| LTM Mar 2026 | $5K USD | +171.4% | — | 0.0% | |
| Peer median (excluding DERM) | — | -70.9% | +30.6% | 5.7% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.42M | 4.72M |
| Deferred Income Tax | 1.57M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.47M | 4.43M | 2.61M | 6.1M | 6.29M |
| Change in Working Capital | 14.71M | 6.19M | (1.66M) | (3.77M) | (11.9M) |
| Accounts Receivables | 768K | (5.38M) | 12.55M | 4.48M | (19.34M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 21.71M | 14.34M | (18.42M) | (2.1M) | (7.27M) |
| Other Working Capital | 686K | (4.52M) | 262K | (1.92M) | 9.91M |
| Other Non-Cash Items | 20.51M | 1.12M | 4.29M | (211K) | (123K) |
| Operating Cash Flow | (2.18M) | (13.53M) | 5.24M | (9.13M) | (12.44M) |
| Capital Expenditures | (10M) | (20M) | (5M) | (15M) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10M) | (20M) | (5M) | (15M) | 0 |
| Debt Repayment | 5.05M | 16.9M | (8.95M) | 8.7M | 15.73M |
| Common Stock Issued | 32.54M | 142K | 4.49M | 8.29M | 16.93M |
| Common Stock Repurchased | 0 | (371K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.97M | (214K) | (350K) | (50K) | (16.43M) |
| Financing Cash Flow | 53.02M | 16.46M | (4.8M) | 16.99M | 16.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 40.84M | (17.08M) | (4.56M) | (7.13M) | 3.79M |
| Free Cash Flow | (12.18M) | (33.53M) | 240K | (9.13M) | (12.44M) |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.